Pluristem Therapeutics Inc. (NASDAQ: PSTI) is -36.07% lower on its value in year-to-date trading and has touched a low of $4.03 and a high of $12.15 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The PSTI stock was last observed hovering at around $4.45 in the last trading session, with the day’s gains setting it 0.07% off its average median price target of $8.50 for the next 12 months. It is also 54.8% off the consensus price target high of $10.00 offered by 2 analysts, but current levels are 35.43% higher than the price target low of $7.00 for the same period.
Currently trading at $4.52, the stock is -0.42% and -14.59% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.22 million and changing 1.57% at the moment leaves the stock -44.01% off its SMA200. PSTI registered -58.26% loss for a year compared to 6-month loss of -52.47%. The firm has a 50-day simple moving average (SMA 50) of $4.8171 and a 200-day simple moving average (SMA200) of $7.2821.
The stock witnessed a 0.89% gain in the last 1 month and extending the period to 3 months gives it a -36.16%, and is 4.39% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.70% over the week and 5.87% over the month.
Pluristem Therapeutics Inc. (PSTI) has around 146 employees, a market worth around $144.46M and $0.00M in sales. Distance from 52-week low is 12.16% and -62.80% from its 52-week high.
Pluristem Therapeutics Inc. (PSTI) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Pluristem Therapeutics Inc. (PSTI) is a “Overweight”. 2 analysts offering their recommendations for the stock have an average rating of 2.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Pluristem Therapeutics Inc. is expected to release its quarterly report on 09/13/2021 and quarterly earnings per share for the current quarter are estimated at -$0.31.The EPS is expected to grow by 94.40% this year.
Pluristem Therapeutics Inc. (PSTI) Top Institutional Holders
50 institutions hold shares in Pluristem Therapeutics Inc. (PSTI), with 5.08M shares held by insiders accounting for 16.10% while institutional investors hold 20.30% of the company’s shares. The shares outstanding are 31.74M, and float is at 26.05M with Short Float at 0.77%. Institutions hold 17.03% of the Float.
The top institutional shareholder in the company is ARK Investment Management, LLC with over 3.96 million shares valued at $27.99 million. The investor’s holdings represent 12.47% of the PSTI Shares outstanding. As of Dec 30, 2020, the second largest holder is Nia Impact Advisors, LLC with 0.29 million shares valued at $2.04 million to account for 0.91% of the shares outstanding. The other top investors are Susquehanna International Group, LLP which holds 0.21 million shares representing 0.65% and valued at over $1.46 million, while Nikko Asset Management Americas, Inc. holds 0.36% of the shares totaling 0.11 million with a market value of $0.8 million.
Pluristem Therapeutics Inc. (PSTI) Insider Activity
A total of 6 insider transactions have happened at Pluristem Therapeutics Inc. (PSTI) in the last six months, with sales accounting for 0 and purchases happening 6 times. The most recent transaction is an insider purchase by CLOVER WOLF CAPITAL – LIMITED , the company’s 10% Owner. SEC filings show that CLOVER WOLF CAPITAL – LIMITED bought 20,000 shares of the company’s common stock on Nov 30 at a price of $9.70 per share for a total of $0.19 million. Following the purchase, the insider now owns 4.08 million shares.
Pluristem Therapeutics Inc. disclosed in a document filed with the SEC on Oct 30 that CLOVER WOLF CAPITAL – LIMITED (10% Owner) bought a total of 50,000 shares of the company’s common stock. The trade occurred on Oct 30 and was made at $9.51 per share for $0.48 million. Following the transaction, the insider now directly holds 4.06 million shares of the PSTI stock.
Still, SEC filings show that on Oct 29, CLOVER WOLF CAPITAL – LIMITED (10% Owner) acquired 20,000 shares at an average price of $9.20 for $0.18 million. The insider now directly holds 4,007,589 shares of Pluristem Therapeutics Inc. (PSTI).